In its June 2023 final guidance, CMS stated that it will monitor whether meaningful competition continues to exist in the market by ongoing assessments of whether the manufacturer of the generic drug or biosimilar is engaging in bona fide marketing. CMS has stated this monitoring will encompass multiple activities, including whether the biosimilar is regularly and consistently available for purchase through the pharmaceutical supply chain, market data, government price reporting, and other sources
As a retrospective cohort analysis, it is inherently subject to biases such as selection bias
Nutritional Neuroscience, 25 (1), 6469
Try a different product name or clear the active filter
GliSODin Cantaloupe Melon Extract improves diet-induced Non-alcoholic Steatohepatitis (NASH) & Non-alcoholic Fatty Liver Disease (NAFLD) outcomes by reducing fat synthesis and improving liver functions through suppressing fat accumulation in the liver & prevent liver fibrosis, improve plasma lipid parameters (total cholesterol, triglycerides & NEFA), reduce liver inflammation and etc